Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213263 · ClinicalTrials.gov registry record · Phase 3
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
A Phase 3 study of Follicular Lymphoma, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 394
- Enrollment target
- 20
- Study locations
NCT02213263 is a Phase 3 study of Follicular Lymphoma that has completed, run by Pfizer. The registered enrollment target is 394 participants, above the 131-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (201% higher). The trial reports 20 study locations across 1 state.
The verdict
NCT02213263, a Phase 3 study of Follicular Lymphoma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 394 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.
Conditions Studied
Interventions
- BIOLOGICAL MabThera®
- BIOLOGICAL PF-05280586
Study Locations (20)
California
- Pacific Cancer Medical Center, Inc. - Anaheim
- The Oncology Institute of Hope and Innovation - Anaheim
- Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc. - Corona
- The Oncology Institute of Hope and Innovation - Downey
- Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc. - Fountain Valley
- Global Cancer Research Institute (GCRI), Inc - Gilroy
- Saint Louise Regional Hospital Radiology Department (Radiology Only) - Gilroy
- South Valley Imaging Center (Imaging Only) - Gilroy
- Los Angeles Hematology Oncology Medical Group - Glendale
- The Oncology Institute of Hope and Innovation - Glendale
- Los Angeles Hematology Oncology Medical Group - Glendale
- The Oncology Institute of Hope and Innovation - Long Beach
- Los Angeles Hematology Oncology Medical Group - Los Angeles
- Los Angeles Hematology Oncology Medical Group - Los Angeles
- The Oncology Institute of Hope and Innovation - Lynwood
- The Oncology Institute of Hope and Innovation - Montebello
- Comprehensive Cancer Center at Desert Regional Medical Center - Palm Springs
- Torrance Health Association DBA, Torrance Memorial Physician, Network/Cancer Care Associates - Redondo Beach
- Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc. - Riverside
- Global Cancer Research Institute, Inc. - San Jose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2014-09-30 |
| Est. Completion | 2018-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02213263
The ClinicalTrials.gov registry entry for NCT02213263 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 131-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (201% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which MabThera® is the first listed.
NCT02213263 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02213263 about?
NCT02213263 is a clinical study titled "A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)". This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is simil...
What is the current status of trial NCT02213263?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 394 participants. The study started on 2014-09-30. Estimated completion is 2018-04-19.
What conditions does trial NCT02213263 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT02213263?
The interventions under investigation include: MabThera® (BIOLOGICAL), PF-05280586 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02213263?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02213263 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RECRUITING · Phase 3
-
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
RECRUITING · Phase 3
-
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
ACTIVE NOT RECRUITING · Phase 3
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.